Body mass index ≥25 kg/m2 associated with greater likelihood of female pattern hair loss
THURSDAY, Feb. 24, 2022 (HealthDay News) — About half of postmenopausal women experience female pattern hair loss (FPHL), according to a study published online Feb. 14 in Menopause.
Sukanya Chaikittisilpa, M.D., from Chulalongkorn University and King Chulalongkorn Memorial Hospital in Bangkok, Thailand, and colleagues assessed the prevalence of FPHL in healthy postmenopausal women. The analysis included 178 postmenopausal women (aged 50 to 65 years).
The researchers found that the prevalence of FPHL was 52.2 percent. FPHL severity, as measured by Ludwig classification, was 73.2 percent for grade I, 22.6 percent for grade II, and 4.3 percent for grade III. Age, time since menopause, and body mass index (BMI) were all significantly associated with FPHL, but when adjusting for age and family history of FPHL, only BMI ≥25 kg/m2 was significantly associated with FPHL (adjusted odds ratio, 2.65).
“Female pattern hair loss was prevalent and associated with lower self-esteem in healthy postmenopausal women in this small cross-sectional study,” Stephanie Faubion, M.D., medical director of the North American Menopause Society, said in a statement. “A better understanding of the mechanisms responsible for this common type of hair loss in women may lead to more effective preventive strategies and treatment options.”
Abstract/Full Text (subscription or payment may be required)
MHT Initiation May Reduce Cardiovascular Risk in Women With Vasomotor Symptoms
Longer Reproductive Lifespan Tied to Lower Bronchiectasis Risk in Postmenopausal Women
Midlife Onset of Increasing Pulse Pressure Not Linked to Menopause
Estrogen Hormone Treatment May Be Beneficial for Brain Fog Symptoms in Menopausal Women
Brain Abnormalities Identified in Children at Risk for Schizophrenia
Cortical Atrophy in Early-Onset Alzheimer Disease Signature Can Predict Progression to Dementia
Menopausal Hormone Therapy Use Linked to Lower Risk for Alzheimer Disease
AMH Predicts Benefit of Chemo + Endocrine Therapy in Under 55s With Breast Cancer